



RAPPORTI ISTISAN 20|16

ISSN: 1123-3117 (cartaceo) • 2384-8936 (online)

Results of the proficiency test on plant protection products in 2020

A. Santilio, C. Pompili,
R. Cammarata, A. Giambenedetti



AMBIENTE
E SALUTE

ISTITUTO SUPERIORE DI SANITÀ

Results of the proficiency test on plant protection products in 2020

Angela Santilio, Chiara Pompili,
Roberto Cammarata, Arianna Giambenedetti

Dipartimento Ambiente e Salute

ISSN: 1123-3117 (cartaceo) • 2384-8936 (online)

**Rapporti ISTISAN
20/16**

Istituto Superiore di Sanità

Results of the proficiency test on plant protection products in 2020.

Angela Santilio, Chiara Pompili, Roberto Cammarata, Arianna Giambenedetti

2020, v, 46 p. Rapporti ISTISAN 20/16

In 2019, the third Proficiency Test (PT) on plant protection products available on the Italian market was organized. The aim of the trial was to find out the quantity of active ingredient on the different formulations of the plant protection products. Eight Italian laboratories and seventeen to worldwide laboratories, which routinely deal with pesticides, were invited to participate. Laboratories are not obligated to take part in the PT; by the way, all the participants sent their results. All laboratories obtained data with acceptable values of z-score within the limits, except for three of them which got higher than -3,5 z-score values for the active substances Azoxystrobin, two laboratories obtained values > +3,5 in the analysis of Epiconazole, two laboratories obtained values > +3,5 and value < 3,5 for Fludioxonil, for Metalaxyl-M and for Thiabendazole.

Key words: Proficiency test; Plant protection products; Azoxystrobin; Epiconazole; Fludioxonil; Metalaxyl-M; Pyraclostrobin; Thiabendazole

Istituto Superiore di Sanità

Risultati dell'esercizio interlaboratorio sui prodotti fitosanitari nel 2020.

Angela Santilio, Chiara Pompili, Roberto Cammarata, Arianna Giambenedetti

2020, v, 46 p. Rapporti ISTISAN 20/16 (in inglese)

Nel 2019 è stato organizzato il terzo esercizio interlaboratorio su prodotti fitosanitari disponibili sul mercato nazionale. L'esercizio riguardava la determinazione del contenuto di principio attivo presente in prodotti fitosanitari di diversa formulazione. Sono stati invitati a partecipare 8 laboratori italiani preposti al controllo dei prodotti fitosanitari e 17 laboratori mondiali interessati ai controlli sui prodotti fitosanitari. La partecipazione è su base volontaria e hanno aderito tutti i partecipanti. Tutti i laboratori hanno ottenuto risultati con valori di z-score entro i limiti definiti ad eccezione di 3 laboratori che hanno ottenuto valori di z-score > -3,5 per la sostanza Azoxystrobin, 2 laboratori hanno ottenuto un valore > +3,5 nell'analisi dell'Epiconazole, 2 laboratori hanno ottenuto un valore > +3,5 e uno < di 3,5 per il Fludioxonil, per il Metalaxyl-M e per il Thiabendazole.

Parole chiave: Esercizio interlaboratorio; Prodotti fitosanitari; Azoxystrobin; Epiconazole; Fludioxonil; Metalaxyl-M; Pyraclostrobin; Thiabendazole

Per informazioni su questo documento scrivere a: angela.santilio@iss.it

Il rapporto è accessibile online dal sito di questo Istituto: www.iss.it

Citare questo documento come segue:

Santilio A, Pompili C, Cammarata R, Giambenedetti A. *Results of the proficiency test on plant protection products in 2020*. Roma: Istituto Superiore di Sanità; 2020. (Rapporti ISTISAN 20/16).

Legale rappresentante dell'Istituto Superiore di Sanità: *Silvio Brusafarro*

Registro della Stampa - Tribunale di Roma n. 114 (cartaceo) e n. 115 (online) del 16 maggio 2014

Direttore responsabile della serie: *Paola De Castro*

Redazione: *Sandra Salinetti e Manuela Zazzara*

La responsabilità dei dati scientifici e tecnici è dei singoli autori, che dichiarano di non avere conflitti di interesse.

TABLE OF CONTENTS

| | |
|---|-----|
| Abbreviations | iii |
| Preface | v |
| Introduction | 1 |
| 1. Proficiency Test on Plant Protection Products | 2 |
| 1.1. Test materials | 2 |
| 1.2. Description of the active substances in the PPPs | 2 |
| 1.2.1. Azoxystrobin..... | 2 |
| 1.2.2. Epoxiconazole..... | 3 |
| 1.2.3. Fludioxonil..... | 3 |
| 1.2.4. Metalaxyl-M | 3 |
| 1.2.5. Pyraclostrobin | 4 |
| 1.2.6. Thiabendazole..... | 4 |
| 1.3. Homogeneity and stability test..... | 4 |
| 1.3.1. Homogeneity..... | 4 |
| 1.3.2. Stability..... | 6 |
| 1.4. Distribution of the samples and instructions for the participants..... | 9 |
| 1.5. Statistical evaluation of results..... | 9 |
| 1.5.1. Robust mean | 10 |
| 1.5.2. Robust estimate of standard deviation | 10 |
| 1.5.3. Calculation of modified z-scores | 10 |
| 1.5.4. Presentation of data..... | 10 |
| 2. Analysis of the substances | 11 |
| 2.1. Azoxystrobin..... | 11 |
| 2.2. Epoxiconazole..... | 12 |
| 2.3. Fludioxonil..... | 13 |
| 2.4. Metalaxyl-M | 14 |
| 2.5. Pyraclostrobin | 15 |
| 2.6. Thiabendazole | 16 |
| 3. Results | 17 |
| References | 36 |
| Appendix A | |
| The announcement letter | 37 |
| Appendix B | |
| Calendar and list of participants..... | 41 |
| Glossary | 45 |

ABBREVIATIONS

| | |
|----------------|--|
| AFSCA | Agence Fédérale pour la Sécurité de la Chaîne Alimentaire (Federal Agency for the Safety of the Food Chain) |
| AAPCO | Association of American Pesticide Control Officials |
| CAS | Chemical Abstract Service |
| CIPAC | Collaborative International Pesticide Analytical Council |
| CV | Coefficient of Variation |
| GC | Gas Chromatography |
| GR | Granules |
| ISO | International Organization for Standardization |
| ITPT | Italian Proficiency Test |
| LC | Liquid Chromatography |
| MAD | Median absolute deviation |
| MS | Mass Spectrometry |
| N/A | Not Available |
| PDA | PhotoDiode Array |
| PPP | Plant Protection Product |
| PPP01 | Plant Protection Product number 1 |
| PPP02 | Plant Protection Product number 2 |
| PPP03 | Plant Protection Product number 3 |
| PPP04 | Plant Protection Product number 4 |
| PT | Proficiency Test |
| SD | Standard Deviation |
| SE | Suspo-Emulsion |
| SL | Soluble Concentrate |
| UV | UltraViolet |
| VWD | Variable Wavelength Detector |
| z-score | Standard Score |

Symbols

| | |
|------------------------------|--|
| σ_p | standard deviation for proficiency test |
| T-test | statistic test of Student's t distribution |

PREFACE

The European legislation – Regulation (EC) 1107/2009 – on Plant Protection Products (PPPs) regulates the authorisation, placing on the market, use and control of PPPs and of any active substance, safener, synergist, co-formulant and adjuvant, which they might contain or of which they might consist of. The objective of those rules is to ensure a high level of protection of both human and animal health and of the environment through evaluation of the risks posed by PPPs, while improving the functioning of the Union market through harmonisation of the rules for their placing on the market and improving agricultural production.

In addition, the Regulation (EU) 2017/625 establishes a harmonised European Union framework for the organisation of official controls and official activities taking into account the rules on official controls laid down in Regulation (EC) 882/2004 and in relevant sectoral legislation, and the experience gained from the application of those rules.

The laboratories designated by the competent authorities to perform analyses on PPP samples taken in the context of official controls should possess the expertise, equipment, infrastructure and staff to carry out such tasks to the highest standards. To ensure sound and reliable results, those laboratories should be accredited for the use of these methods according to standard EN ISO/IEC 17025.

One of the instruments to reach a high-quality standard and performance is the participation in the interlaboratory test (Proficiency Test, PT) to demonstrate that the analytical data obtained from laboratories are reliable.

In the area of PPPs there are two organizations that plan PTs:

- Association of American Pesticide Control Officials (AAPCO)
International organization that schedules PT on the active ingredient content on PPP on the basis of the American monitoring programmes.
- Agence Fédérale pour la Sécurité de la Chaîne Alimentaire (AFSCA)
European organization that plans PT on physical chemical properties for PPPs.

For this reason, it is important to organize PTs for the active ingredient content for the national official laboratories. This activity was planned in the framework of the collaboration with Ministry of Health and the Istituto Superiore di Sanità (ISS, the National Institute of Health in Italy). As the national monitoring programs are in comply with the European monitoring programs, it is useful to enlarge the invitation to European Member State laboratories that work on these issues. In addition, two laboratories from Argentina and Brazil joined.

INTRODUCTION

In January 2020, all relevant Italian laboratories, 15 European Member State laboratories and 2 laboratories from Argentina and Brazil were invited to participate in the 3rd Italian PT on PPPs (later indicated as ITPT2020).

The announcement letter (Appendix A) sent to the laboratories on 15th January, according to the calendar the laboratories was asked to forward the invitation. The invitation was sent to 8 Italian laboratories, 15 European Member State laboratories and 2 laboratories from Argentina and Brazil.

For the PT four different commercial products containing six active ingredients (Azoxystrobin 1.33%, Epoxiconazole 6.02%, Fludioxonil 3.32%, Metalaxyl-M 2.57%, Pyraclostrobin 8.17%, and Thiabendazole 26.55%) were shipped to the laboratories.

1. PROFICIENCY TEST ON PLANT PROTECTION PRODUCTS

1.1. Test materials

The test materials of the ITPT2020 consisted of four PPPs obtained from manufacturer and available from Italian market.

The product types are: Soluble Concentrate (SL) and Suspo-Emulsion (SE) at a declared concentration reported in Table 1.


Table 1. Test materials of ITPT2020

| Check Sample N. | Product description | Active ingredient | Declared level % |
|-----------------|---------------------|-------------------|------------------|
| PPP01 | Soluble Concentrate | Azoxystrobin | 1.33 |
| PPP02 | Suspo-Emulsion | Epoxiconazole | 6.02 |
| PPP03 | Soluble Concentrate | Fludioxonil | 3.32 |
| PPP04 | Soluble Concentrate | Metalaxyl-M | 2.57 |
| PPP05 | Suspo-Emulsion | Pyraclostrobin | 8.17 |
| PPP06 | Soluble Concentrate | Thiabendazole | 26.55 |


For the preparation of the subsamples to send each laboratory, the PPPs were mixed mechanically and shared in 25 samples for a total of 50 plastic containers sealed and stored at ambient temperature before the shipment to the participants. Each laboratory received two samples. Nothing was added to our samples.

1.2. Description of the active substances in the PPPs

1.2.1. Azoxystrobin

| | |
|---|--|
|  | Common name Methyl (2E)-2-[2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate |
| | Structure formula C ₂₂ H ₁₇ N ₃ O ₅ |
| | CAS number 131860-33-8 Azoxystrobin has a molecular weight of 403.388 g/mol. It has moderate solubility in water, formulations aid its use in water sprays by creating an emulsion when diluted; is compatible with many others pesticides and adjuvants when mixed. It belongs to the class of QoI (Quinone outside Inhibitors) Fungicides. It is often used on more than 50 crops and in the year 2000 it was announced that it had been granted UK Millennium product status. |


1.2.2. Epoxiconazole

| | |
|---|--|
|  | <p>Common name (2RS,3SR)-1-[3-(2-chlorophenyl)-2,3-epoxy-2-(4-fluorophenyl)propyl]-1H-1,2,4-triazole</p> <p>Structure formula C₁₇H₁₃CIFN₃O</p> <p>CAS number 135319-73-2</p> <p>Epoxiconazole is a fungicide from the class of the azoles developed to protect crops with the inhibition of the metabolism of fungi cells preventing the growth of the mycelia (fungal cells) and limiting the production of conidia (mitospores). It has a molecular weight of 329.76 g/mol. Epoxiconazole is used on many crops like cereals, soybeans, banana, rice, coffee.</p> |
|---|--|


1.2.3. Fludioxonil

| | |
|--|---|
|  | <p>Common name 4-(2,2-Difluoro-1,3-benzodioxol-4-yl)-1H-pyrrole-3-Carbonitrile</p> <p>Structure formula C₁₂H₆F₂O₂N₂</p> <p>CAS number 131341-86-1</p> <p>Fludioxonil is a non-systemic fungicide, used for the treatment of crops like cereals, fruit and vegetables in combination with another fungicide. Its mode of action is to inhibit transport-associated phosphorylation of glucose which reduces mycelia growth rate. It is toxic to fish and other aquatic organisms. It has a molecular weight of 248.189 g/mol.</p> |
|--|---|


1.2.4. Metalaxyl-M

| | |
|---|---|
|  | <p>Common name Methyl 2-[(2,6-dimethylphenyl)(methoxyacetyl)amino]propanoate</p> <p>Structure formula C₁₅H₂₁NO₄</p> <p>CAS number 57837-19-1</p> <p>Metalaxyl-M is an acylalanine fungicide with a systemic function. Metalaxyl-M is the name for the optically pure (-)/D/ R active stereoisomer which is also known as Mefenoxam. It has a molecular weight of 279.33 g/mol. Metalaxyl-M is used agriculturally as a systemic fungicide on fruits like oranges or apples and potatoes.</p> |
|---|---|

1.2.5. Pyraclostrobin

| | |
|---|---|
|  | <p>Common name Methyl {2-[1-(4-chlorophenyl)-1H-pyrazol-3-yloxymethyl]phenyl}methoxycarbamate</p> <p>Structure formula C₁₉H₁₈CIN₃O₄</p> <p>CAS number 175013-18-0</p> <p>Pyraclostrobin is a fungicide belonging to the group which is collectively known as strobilurins, which inhibit mitochondrial respiration. It has a molecular weight of 387.82 g/mol and it is largely used on grapes and potatoes.</p> |
|---|---|

1.2.6. Thiabendazole

| | |
|--|---|
|  | <p>Common name 2-(4-thiazolyl)-1H-benzimidazole</p> <p>Structure formula C₁₀H₇N₃S</p> <p>CAS number 148-79-8</p> <p>Thiabendazole is a preservative, an anti-fungal agent and an anti-parasitic agent. It is used primarily to control mold, blight, and other fungal diseases in fruits and vegetables. It is also used as a food additive, a preservative with E number E233 (INS number 233). For example, it is applied to bananas to ensure freshness, and is a common ingredient in the waxes applied to the skins of citrus fruits. It has a molecular weight of 201.25 g/mol.</p> |
|--|---|

1.3. Homogeneity and stability test

Homogeneity and stability tests were performed according to the ISO 13528:2015(E) - Annex B and the International Harmonized Protocol.

1.3.1. Homogeneity

Regarding the homogeneity test, ten bottles were randomly chosen and analysed in duplicate, in two different days.

Considering that the σ_{PT} is unknown, the statistically significant differences between PT items used was evaluated with the analysis of variance T-test at $\alpha=0.05$, if the data series are more than two will need the Fisher Test. The T-test shows a significance level (P) higher than 0.05 for each active substance. It is possible to say the samples are not different one each other: they are homogeneous.

The results are shown in the Table 2 for all compounds.

Table 2. Homogeneity results of the PT samples

| Sample ID | Azoxystrobin | | Epoxiconazole | | Fludioxonil | | Metalaxyl-M | | Pyraclostrobin | | Thiabendazole | |
|-------------|--------------|------|---------------|------|-------------|------|-------------|------|----------------|------|---------------|-------|
| | a | b | a | b | a | b | a | b | a | b | a | b |
| #1 | 1.32 | 1.34 | 6.04 | 6.07 | 3.34 | 3.08 | 2.32 | 2.41 | 8.42 | 8.35 | 27.60 | 27.40 |
| | 1.31 | 1.27 | 5.97 | 5.96 | 3.30 | 3.35 | 2.44 | 2.41 | 8.39 | 8.34 | 27.48 | 27.35 |
| | 1.25 | 1.30 | 6.05 | 6.11 | 3.28 | 3.23 | 2.36 | 2.57 | 8.33 | 8.33 | 27.51 | 26.57 |
| | 1.23 | 1.25 | 5.98 | 6.04 | 3.34 | 3.45 | 2.51 | 2.49 | 8.34 | 8.38 | 27.33 | 27.46 |
| | 1.29 | 1.25 | 6.08 | 5.93 | 3.47 | 3.22 | 2.57 | 2.41 | 8.43 | 8.45 | 27.42 | 25.95 |
| | 1.25 | 1.22 | 6.09 | 6.03 | 3.39 | 3.03 | 2.48 | 2.41 | 8.35 | 8.36 | 26.26 | 26.00 |
| | 1.26 | 1.27 | 6.01 | 5.96 | 3.33 | 3.44 | 2.69 | 2.51 | 8.32 | 8.39 | 25.68 | 25.67 |
| | 1.32 | 1.27 | 5.88 | 5.91 | 3.40 | 3.28 | 2.38 | 2.60 | 8.41 | 8.45 | 25.71 | 25.66 |
| | 1.28 | 1.20 | 6.01 | 5.96 | 3.37 | 3.27 | 2.55 | 2.57 | 8.39 | 8.46 | 26.03 | 25.79 |
| | 1.27 | 1.25 | 5.96 | 5.98 | 3.44 | 3.39 | 2.52 | 2.54 | 8.34 | 8.42 | 25.87 | 26.12 |
| Mean | 1.27 | | 6.00 | | 3.32 | | 2.49 | | 8.38 | | 26.54 | |
| SD | 0.04 | | 0.06 | | 0.12 | | 0.09 | | 0.05 | | 0.79 | |
| t** | | | 1.09 | | 0.43 | | 1.92 | | 0.21 | | 0.83 | |
| P*** | | | 0.29 | | 0.64 | | 0.07 | | 0.83 | | 0.42 | |
| Homogeneity | | YES | | YES | | YES | | YES | | YES | | YES |

a, b: replicates of the same sample

t**: T of Student Test

P***: significance level;

SD: Standard Deviation

1.3.2. Stability

The stability test was performed using two bottles, randomly chosen, which were analysed in duplicate in two occasions and each occasion twice:

- *Day 1*: before the shipment of the samples in January 2020;
- *Day 2*: at the deadline for reporting results in May 2020.

Stability test was judged acceptable as the percentage difference of concentration, for each active substance was found less than 10%. As presented in Table 3, there was a slight decrease in the pesticide concentration of Metalaxyl-M showed during the PT, but still acceptable.

Table 3. Summary of stability data (ITPT2020)

| Active Ingredient | Analysis January | Analysis May | Declared Level % |
|-------------------|------------------|--------------|------------------|
| Azoxystrobin | 1.26 | 1.32 | 1.33 |
| Epoxiconazole | 6.15 | 5.98 | 6.02 |
| Fludioxonil | 3.48 | 3.21 | 3.32 |
| Metalaxyl-M | 2.74 | 2.63 | 2.57 |
| Pyraclostrobin | 8.22 | 8.48 | 8.17 |
| Thiabendazole | 26.08 | 26.61 | 26.55 |

Tables 4, 5, 6, 7, 8 and 9 show the individual results for each substance. The deviation calculated with reference to the 1st analysis and to the declared label shows a deviation less than 10% for all substances. The products are stable.

Table 4. AZOXYSTROBIN: results of stability test (ITPT2020)

| Parameter | January | | | | May | | | | | | | |
|--|-------------|-------|----------------|-------|-------------|-------|-------------|-------|--|--|--|--|
| | Replicate 1 | | Replicate 2 | | Replicate 1 | | Replicate 2 | | | | | |
| | inj 1 | inj 2 | inj 1 | inj 2 | inj 1 | inj 2 | inj 1 | inj 2 | | | | |
| Sample 1 | 1.27 | 1.27 | 1.24 | 1.2 | 1.26 | 1.50 | 1.35 | 1.27 | | | | |
| Sample 2 | 1.37 | 1.36 | 1.25 | 1.21 | 1.18 | 1.25 | 1.29 | 1.34 | | | | |
| Mean | 1.31 | | 1.21 | | 1.29 | | 1.34 | | | | | |
| SD | 0.06 | | 0.02 | | 0.14 | | 0.04 | | | | | |
| Mean of 2 days | 1.26 | | | | 1.32 | | | | | | | |
| Standard Deviation of 2 days | 0.02 | | | | 0.07 | | | | | | | |
| Deviation (ref 1st Analysis %)/ [(M2-M1)/M1]*100 | 4.35 | | | | | | | | | | | |
| Deviation (ref to declared label %)/ [(SM-1.33)/1.33]*100 | -2.91 | | | | | | | | | | | |
| Stability Mean | 1.29 | | Declared Label | | 1.33 | | | | | | | |
| Stability Standard Deviation | 0.03 | | CV % | | 2.70 | | | | | | | |

Table 5. EPOXICONAZOLE: results of stability test (ITPT2020)

| Parameter | January | | | | May | | | | | | | | | | | |
|--|-------------|-------|-------------|----------------|-------------|-------|-------------|-------|--|--|--|--|--|--|--|--|
| | Replicate 1 | | Replicate 2 | | Replicate 1 | | Replicate 2 | | | | | | | | | |
| | inj 1 | inj 2 | inj 1 | inj 2 | inj 1 | inj 2 | inj 1 | inj 2 | | | | | | | | |
| Sample 1 | 6.03 | 6.04 | 6.07 | 5.99 | 5.99 | 6.03 | 6 | 5.82 | | | | | | | | |
| Sample 2 | 6.02 | 6.18 | 6.18 | 6.24 | 6.08 | 6.02 | 6.02 | 5.92 | | | | | | | | |
| Mean | 6.07 | | 6.24 | | 6.03 | | 5.92 | | | | | | | | | |
| SD | 0.08 | | 0.11 | | 0.04 | | 0.09 | | | | | | | | | |
| Mean of 2 days | 6.15 | | | | 5.98 | | | | | | | | | | | |
| Standard Deviation of 2 days | 0.03 | | | | 0.04 | | | | | | | | | | | |
| Deviation (ref 1st Analysis %)/ [(M2-M1)/M1]*100 | -2.90 | | | | | | | | | | | | | | | |
| Deviation (ref to declared label %)/ [(SM-6.02)/6.02]*100 | 0.74 | | | | | | | | | | | | | | | |
| Stability Mean | 6.06 | | | Declared Label | | 6.02 | | | | | | | | | | |
| Stability Standard Deviation | 0.01 | | | CV % | | 0.14 | | | | | | | | | | |

Table 6. FLUDIOXONIL: results of stability test (ITPT2020)

| Parameter | January | | | | May | | | | | | | | | | | |
|--|-------------|-------|-------------|----------------|-------------|-------|-------------|-------|--|--|--|--|--|--|--|--|
| | Replicate 1 | | Replicate 2 | | Replicate 1 | | Replicate 2 | | | | | | | | | |
| | inj 1 | inj 2 | inj 1 | inj 2 | inj 1 | inj 2 | inj 1 | inj 2 | | | | | | | | |
| Sample 1 | 3.28 | 3.4 | 3.36 | 3.31 | 2.99 | 3.62 | 3.24 | 3.18 | | | | | | | | |
| Sample 2 | 3.63 | 3.61 | 3.39 | 3.47 | 3.29 | 3.5 | 3.02 | 3.06 | | | | | | | | |
| Mean | 3.48 | | 3.47 | | 3.35 | | 3.06 | | | | | | | | | |
| SD | 0.17 | | 0.07 | | 0.28 | | 0.10 | | | | | | | | | |
| Mean of 2 days | 3.48 | | | | 3.21 | | | | | | | | | | | |
| Standard Deviation of 2 days | 0.07 | | | | 0.12 | | | | | | | | | | | |
| Deviation (ref 1st Analysis %)/ [(M2-M1)/M1]*100 | -7.77 | | | | | | | | | | | | | | | |
| Deviation (ref to declared label %)/ [(SM-3.32)/3.32]*100 | 0.60 | | | | | | | | | | | | | | | |
| Stability Mean | 3.34 | | | Declared Label | | 3.32 | | | | | | | | | | |
| Stability Standard Deviation | 0.04 | | | CV % | | 1.07 | | | | | | | | | | |

Table 7. METALAXYL-M: results of stability test (ITPT2020)

| Parameter | January | | | | May | | | | | | | | | | | |
|--|-------------|-------|-------------|----------------|-------------|-------|-------------|-------|--|--|--|--|--|--|--|--|
| | Replicate 1 | | Replicate 2 | | Replicate 1 | | Replicate 2 | | | | | | | | | |
| | inj 1 | inj 2 | inj 1 | inj 2 | inj 1 | inj 2 | inj 1 | inj 2 | | | | | | | | |
| Sample 1 | 2.77 | 2.73 | 2.63 | 2.67 | 2.74 | 2.64 | 2.84 | 2.82 | | | | | | | | |
| Sample 2 | 2.58 | 2.68 | 2.71 | 2.79 | 2.59 | -- | 2.63 | 2.61 | | | | | | | | |
| Mean | 2.69 | | 2.79 | | 2.66 | | 2.61 | | | | | | | | | |
| SD | 0.08 | | 0.07 | | 0.08 | | 0.12 | | | | | | | | | |
| Mean of 2 days | 2.74 | | | | 2.63 | | | | | | | | | | | |
| Standard Deviation of 2 days | 0.01 | | | | 0.03 | | | | | | | | | | | |
| Deviation (ref 1st Analysis %)/ [(M2-M1)/M1]*100 | -3.89 | | | | | | | | | | | | | | | |
| Deviation (ref to declared label %)/ [(SM-2.57)/2.57]*100 | 4.54 | | | | | | | | | | | | | | | |
| Stability Mean | 2.69 | | | Declared Label | | 2.57 | | | | | | | | | | |
| Stability Standard Deviation | 0.02 | | | CV % | | 0.59 | | | | | | | | | | |

Table 8. PYRACLOSTROBIN: results of stability test (ITPT2020)

| Parameter | January | | | | May | | | | | | | | | | | |
|--|-------------|-------|-------------|----------------|-------------|-------|-------------|-------|--|--|--|--|--|--|--|--|
| | Replicate 1 | | Replicate 2 | | Replicate 1 | | Replicate 2 | | | | | | | | | |
| | inj 1 | inj 2 | inj 1 | inj 2 | inj 1 | inj 2 | inj 1 | inj 2 | | | | | | | | |
| Sample 1 | 8.31 | 8.33 | 8.2 | 8.14 | 8.42 | 8.4 | 8.61 | 8.57 | | | | | | | | |
| Sample 2 | 8.18 | 8.13 | 8.23 | 8.20 | 8.34 | 8.33 | 8.57 | 8.58 | | | | | | | | |
| Mean | 8.24 | | 8.2 | | 8.37 | | 8.58 | | | | | | | | | |
| SD | 0.10 | | 0.04 | | 0.04 | | 0.02 | | | | | | | | | |
| Mean of 2 days | 8.22 | | | | 8.48 | | | | | | | | | | | |
| Standard Deviation of 2 days | 0.04 | | | | 0.02 | | | | | | | | | | | |
| Deviation (ref 1st Analysis %)/ [(M2-M1)/M1]*100 | 3.13 | | | | | | | | | | | | | | | |
| Deviation (ref to declared label %)/ [(SM-8.17)/8.17]*100 | 2.17 | | | | | | | | | | | | | | | |
| Stability Mean | 8.35 | | | Declared Label | | 8.17 | | | | | | | | | | |
| Stability Standard Deviation | 0.02 | | | CV % | | 0.21 | | | | | | | | | | |

Table 9. THIABENDAZOLE: results of stability test (ITPT2020)

| Parameter | January | | | | May | | | | | | | | | | | |
|--|-------------|-------|-------------|----------------|-------------|-------|-------------|-------|--|--|--|--|--|--|--|--|
| | Replicate 1 | | Replicate 2 | | Replicate 1 | | Replicate 2 | | | | | | | | | |
| | inj 1 | inj 2 | inj 1 | inj 2 | inj 1 | inj 2 | inj 1 | inj 2 | | | | | | | | |
| Sample 1 | 26.25 | 26.09 | 26.15 | 26.12 | 26.25 | 26.11 | 26.93 | 26.5 | | | | | | | | |
| Sample 2 | 25.91 | 25.96 | 26.06 | 26.11 | 26.21 | 25.32 | 27.22 | 27.24 | | | | | | | | |
| Mean | 26.05 | | 26.11 | | 25.97 | | 27.24 | | | | | | | | | |
| SD | 0.15 | | 0.04 | | 0.44 | | 0.35 | | | | | | | | | |
| Mean of 2 days | 26.08 | | | | 26.61 | | | | | | | | | | | |
| Standard Deviation of 2 days | 0.08 | | | | 0.07 | | | | | | | | | | | |
| Deviation (ref 1st Analysis %)/ [(M2-M1)/M1]*100 | 2.01 | | | | | | | | | | | | | | | |
| Deviation (ref to declared label %)/ [(SM-26.55)/26.55]*100 | -0.78 | | | | | | | | | | | | | | | |
| Stability Mean | 26.34 | | | Declared Label | | 26.55 | | | | | | | | | | |
| Stability Standard Deviation | 0.01 | | | CV % | | 0.04 | | | | | | | | | | |

1.4. Distribution of the samples and instructions for the participants

Two plastic transparent containers with red cup were filled (one with SL and SE products). Each sample was shipped to the participating laboratories at ambient temperature. An information message was sent out by e-mail during shipment so that laboratories make their own arrangements for the reception of the package, and a protocol was sent by e-mail.

The participants (Appendix B) were asked:

- to inform on the safe recipient of the samples in their laboratories;
- to report results in the appropriate form and send them to the organizer by e-mail along with the details of methodology used.

The samples were sent to the participant on 15th January 2020.

The deadline for results was 30th of June 2020.

The final report was dispatched to all participant at the end of July 2020.

1.5. Statistical evaluation of results

This PT has been evaluated using the modified z-score parameter to rate the laboratory performance for each active substance according to AAPCO protocol.

The outliers were calculated using the modified z-score.

1.5.1. Robust mean

The purpose of using a robust estimator for the mean was to cope with the possibility of outlying data points without having to remove them from the sample.

The robust mean estimator used was the median.

1.5.2. Robust estimate of standard deviation

The robust estimate of the standard deviation used was the MAD_E value.

To obtain the MAD_E , calculate Median Absolute Deviation (MAD) from the sample median:

$$MAD = \text{median}(|X_i - \text{median}(X_i)|_{i=1,2,\dots,n})$$

Calculate MAD_E :

$$MAD_E = K \times MAD$$

For normally distributed data, $K = 1.483$:

$$MAD_E = 1.483 \times MAD$$

1.5.3. Calculation of modified z-scores

Modified z-scores (Z_i) for each laboratory were calculated as:

$$Z_i = 0.6745 \times \frac{(X_i - \text{median})}{MAD}$$

Z values falling outside the range of $-3.5 \leq Z_i \leq 3.5$ were marked as outliers.

1.5.4. Presentation of data

Data is presented graphically in two ways:

- a scatter plot showing each participating laboratory's two-day mean value for each analyte along with the associated standard deviation. These plots also show the upper and lower Horwitz (Thompson) limits for the sample, as well as median $\pm 2 MAD_E$.
- a plot of modified z-scores.

2. ANALYSIS OF THE SUBSTANCES

Description and statistical evaluation of the results are presented for each compound separately. This year we decide to not apply Horwitz theorem, because the active substances concentrations are high enough to make it unnecessary.

2.1. Azoxystrobin

Regarding the active substance Azoxystrobin, 25 boxes were sent all over the world, in particular 8 to Italian laboratories and 17 to worldwide laboratories outside Italy. We received 21 participation results; the four laboratories missing are all from Italy. Eleven of the laboratories used for the analysis an LC instrument and the other ten the GC: 10 of them with a UV Detector, 9 with an FID Detector and 2 with a MS Detector. It is interesting to note that almost all of the laboratories choose to use an in-house method and just a few of them a CIPAC (Collaborative International Pesticide Analytical Council) method and just two applied a manufacturer's method, as shown in Table 10. At the same time, all the methods gave appreciable data.

Table 10. AZOXYSTROBIN: methods applied for analysis (ITPT2020)

| Laboratories | In-house | CIPAC | Manufacturer's |
|--------------|----------|-------|----------------|
| Number | 16 | 3 | 2 |

On the collected data it was applied a statistical evaluation based on a robust estimator (median) instead the mean. The purpose of this choice was to cope the possibility of outlying data points without having to remove them, so it was used the median and the standard deviation.

Figure 1 shows the lab's values of modified z-score.




Figure 1. AZOXYSTROBIN: modified z-scores (ITPT2020)

The results obtained are laudable data, in fact most of them are inside the modified z-score range of $-3.5 \leq Z \leq +3.5$, three of them are outliers so outside the range of the modified z-score and two are in a “border line zone” so questionable but still an acceptable value.

One laboratory obtained an excellent value of modified z-score of 0.

2.2. Epoxiconazole

For the active substance Epoxiconazole, 25 boxes were sent all over the world, in particular 8 to Italian Laboratories and 17 to worldwide laboratories outside Italy. We received 19 participation results. Fourteen laboratories used for the analysis an LC instrument and the other 5 the GC: 13 of them with a UV Detector, 5 with an FID Detector and 1 with a MS Detector. To carry out this analysis 15 laboratories applied an in-house method, 3 the CIPAC method and just one used the manufacturer's method, as shown in Table 11. At the same time, both the methods gave appreciable data, except for two laboratories who gave unacceptable values, as Figure 2 shows.

Table 11. EPOXICONAZOLE: methods applied for analysis (ITPT2019)

| Laboratories | In-house | CIPAC | Manufacturer's |
|--------------|----------|-------|----------------|
| Number | 15 | 3 | 1 |

As for the Azoxystrobin, on the collected data it was applied a statistical evaluation based on a robust estimator instead the mean. The purpose of this choose was to cope the possibility of outlying data points without having to remove them, so it was used the median and the standard deviation. Figure 2 shows the lab's values of modified z-score.




Figure 2. EPOXICONAZOLE: modified z-scores (ITPT2020)

The results obtained are valuable data, in fact most of them are inside the z-score range of $-3.5 \leq Z \leq +3.5$ and two of them are completely unacceptable in the positive zone and one is questionable.

Three laboratories obtained the excellent value of modified z-score of 0.

2.3. Fludioxonil

Fludioxonil was the third active substance and, as the other two, 25 boxes were sent all over the world, in particular 8 to Italian laboratories and 17 to worldwide laboratories outside Italy. We received 20 participation results; 4 laboratories missing are from Italy and 1 is from outside Italy. The analysis was performed using LC instrument for 15 laboratories and the other 5 decide to use the GC: 14 of them with a UV Detector, 4 with FID Detector and 2 with a MS Detector. Some of the laboratories choose to use an in-house method, others a CIPAC method and few others applied a manufacturer's method, as shown in Table 12. At the same time, all the methods gave appreciable data.

Table 12. FLUDIOXONIL: methods applied for analysis (ITPT2020)

| Laboratories | In-house | CIPAC | Manufacturer's |
|--------------|----------|-------|----------------|
| Number | 18 | 0 | 2 |

As for the other two active substances mentioned before, on the collected data it was applied a statistical evaluation based on a robust estimator (median) instead the mean. The purpose of this choice was to cope the possibility of outlying data points without having to remove them, so it was used the median and the standard deviation.

Figure 3 shows the lab's values of modified z-score.




Figure 3. FLUDIOXONIL: modified z-scores (ITPT2020)

The results obtained are valuable data, in fact most of them are inside the z-score Range of $-3.5 \leq Z \leq +3.5$, two of them is completely unacceptable one in the positive zone and the other one on the negative zone.

Any of the laboratories obtained the excellent value of modified z-score of 0.

2.4. Metalaxyl-M

Metalaxyl-M was the fourth active substance and, as the other three mentioned before, 25 boxes were sent all over the world, in particular 8 to Italian laboratories and 17 to worldwide laboratories outside Italy. We received 20 participation results; 4 laboratories missing are from Italy and 1 is from outside Italy. The analysis was performed using LC instrument for 12 laboratories, 11 of them with a UV Detector and 1 with a MS Detector, 8 laboratories preferred to use GC-FID and 1 GC-MS.

Some of the laboratories choose to use an in-house method, others a CIPAC method and few others applied a manufacturer's method, as shown in Table 13. At the same time, all the methods gave appreciable data.

Table 13. METALAXYL-M: methods applied for analysis (ITPT2020)

| Laboratories | In-house | CIPAC | Manufacturer's |
|--------------|----------|-------|----------------|
| Number | 17 | 1 | 2 |

On the collected data it was applied a statistical evaluation based on a robust estimator (median) instead the mean. The purpose of this choose was to cope the possibility of outlying data points without having to remove them, so it was used the median and the standard deviation.

Figure 4 shows the lab's values of modified z-score.




Figure 4. METALAXYL-M: modified z-scores (ITPT2020)

The results obtained are valuable data, in fact most of them are inside the z-score range of $-3.5 \leq Z \leq +3.5$, two of them are completely unacceptable one in the positive zone and the other one in the negative zone.

No laboratory obtained the excellent value of modified z-score of 0.

2.5. Pyraclostrobin

Pyraclostrobin was the fifth active substance and, as the other four mentioned before, 25 boxes were sent all over the world, in particular 8 to Italian laboratories and 17 to worldwide laboratories outside Italy. We received 21 participation results; 4 laboratories missing are all from Italy. All the analysis was performed using LC instrument: 20 of them with a UV Detector and 1 with a MS Detector. Some of the laboratories choose to use an In-house method, others a CIPAC method and few others applied a manufacturer's method, as shown in Table 14. At the same time, all the methods gave appreciable data.

Table 14. PYRACLOSTROBIN: methods applied for analysis (ITPT2020)

| Laboratories | In-house | CIPAC | Manufacturer's |
|--------------|----------|-------|----------------|
| Number | 16 | 4 | 1 |

On the collected data it was applied a statistical evaluation based on a robust estimator (median) instead the mean. The purpose of this choose was to cope the possibility of outlying data points without having to remove them, so it was used the median and the standard deviation.

Figure 5 shows the lab's values of modified z-score. The results obtained are valuable data, in fact most all of them are inside the z-score range of $-3.5 \leq Z \leq +3.5$, just two of them are in the questionable zone.

No laboratory obtained the excellent value of modified z-score of 0.




Figure 5. PYRACLOSTROBIN: modified z-scores (ITPT2020)

2.6. Thiabendazole

Thiabendazole was the sixth active substance, 25 boxes were sent all over the world, in particular 8 to Italian laboratories and 17 to worldwide laboratories outside Italy. We received 17 participation results; 4 laboratories missing are all from Italy and 4 Laboratories missing all from Worldwide. Sixteen laboratories used for the analysis an LC instrument: 15 of them with a UV Detector and 1 with a MS Detector. Just one lab used the GC-FID.

To carry out this analysis 9 laboratories applied an in-house method, 7 the CIPAC method and just one used the manufacturer's method, as shown in Table 15. At the same time, both the methods gave appreciable data, except for two laboratories, which gave unacceptable values, as Figure 6 shows.

Table 15. Thiabendazole: methods applied for analysis (ITPT2020)

| Laboratories | In-house | CIPAC | Manufacturer's |
|--------------|----------|-------|----------------|
| Number | 9 | 7 | 1 |

On the collected data it was applied a statistical evaluation based on a robust estimator (median) instead the mean. The purpose of this choose was to cope the possibility of outlying data points without having to remove them, so it was used the median and the standard deviation.

Figure 6 shows the lab's values of modified z-score. The results obtained are valuable data, in fact most all of them are inside the z-score range of $-3.5 \leq Z \leq +3.5$, and two of them are completely unacceptable one in the positive zone and one in the negative zone. One laboratory obtained the excellent value of modified z-score of 0.




Figure 6. THIABENDAZOLE: modified z-scores (ITPT2020)

3. RESULTS

The outcome of the ITPT2020 can be considered satisfactory due to the third PT organized by Italy.

The participation of the Italian and worldwide laboratories was good. For Italy, 8 laboratories participated distributed as 5 from the North, 1 from Centre and 2 from South of the Country. Due to the virus situation, 4 laboratories could not take part to our activity. The European laboratories were 15, excluding Italy, distributed as one of the South, 10 of the Centre and 4 of the North of Europe.

The performance of the laboratories expressed in terms of modified z-score was satisfactory by almost all participants for all substances. For each active substance there are outlier values, and the analysis of Azoxystrobin was the most critical while Pyraclostrobin was the most successful.

Almost all of the laboratories preferred to use an in-house method, inspired from the CIPAC and adapted to their lab conditions so with some modification, for example, without using the internal standard.

Based on the results it can be concluded that the PT was successfully organized and we are very glad to say a satisfactory number of people took part with all the inconvenient of this year and we run out our third edition!

Tables 16, 17 and 18 summarize the participation per active ingredient and the results per active ingredient including and excluding the outliers.

For each active substance there were a percentage of failing results obtained with the modified z-score, as Table 16 shows.

Table 16. Summary of participation per active ingredient (ITPT2020)

| Check sample n. | Product description | Active ingredient | Participants (n.) | Labs using GC (n.) | Labs using LC (n.) | Failing results ¹ (%) |
|-----------------|---------------------|-------------------|-------------------|--------------------|--------------------|----------------------------------|
| PPP01 | Soluble Concentrate | Azoxystrobin | 21 | 10 | 11 | 0 |
| PPP02 | Suspo-Emulsion | Epoxiconazole | 19 | 5 | 14 | 10.52 |
| PPP03 | Soluble Concentrate | Fludioxonil | 20 | 5 | 15 | 10 |
| PPP04 | Soluble Concentrate | Metalaxyl-M | 20 | 8 | 12 | 10 |
| PPP05 | Suspo-Emulsion | Pyraclostrobin | 21 | 0 | 21 | 0 |
| PPP06 | Soluble Concentrate | Thiabendazole | 17 | 1 | 16 | 11.76 |

¹ Where failing indicates a mean assay result outside the modified z-score defined acceptable limits.

Table 17. Summary of lab results per active ingredient, including outliers (ITPT2020)

| Check sample n. | Analyte (Label claim) | Minimum result | Maximum result | Grand Average | Grand %CV |
|-----------------|-----------------------|----------------|----------------|---------------|-----------|
| PPP01 | Azoxystrobin 1.33% | 1.19 | 1.67 | 1.35 | 8.47 |
| PPP02 | Epoxiconazole 6.02% | 5.79 | 6.63 | 6.04 | 2.73 |
| PPP03 | Fludioxonil 3.32% | 3.1 | 4.32 | 3.37 | 6.14 |
| PPP04 | Metalaxyl-M 2.57% | 2.3 | 3.39 | 2.71 | 0.15 |
| PPP05 | Pyraclostrobin 8.17% | 7.41 | 8.7 | 8.14 | 3.21 |
| PPP06 | Thiabendazole 26.55% | 24.2 | 30.2 | 26.63 | 4.16 |

Table 18. Summary of lab results per active ingredient, excluding outliers

| Check sample n. | Analyte (Label claim) | N. of outliers ¹ | Average excluding outliers | %CV excluding outliers |
|-----------------|-----------------------|-----------------------------|----------------------------|------------------------|
| PPP01 | Azoxystrobin 1.33% | 0 | 1.35 | 8.47 |
| PPP02 | Epoxiconazole 6.02% | 2 | 5.99 | 1.24 |
| PPP03 | Fludioxonil 3.32% | 2 | 3.34 | 2.45 |
| PPP04 | Metalaxyl-M 2.57% | 2 | 2.69 | 2.91 |
| PPP05 | Pyraclostrobin 8.17% | 0 | 8.15 | 2.87 |
| PPP06 | Thiabendazole 26.55% | 2 | 26.47 | 1.83 |

¹ An outlier is flagged when the modified z-score falls outside the range of $-3.5 \leq Zi \leq 3.5$; see Appendix for calculations.

The performance of the laboratories expressed in terms of modified z-score was satisfactory by almost all participants for all substances. For each active substance there are outlier values, and the analysis of Azoxystrobin was the most critical while Pyraclostrobin was the most successful. Almost all of the laboratories used in-house methods, inspired from the CIPAC and adapted to their laboratories' conditions so with some modification, for example, without using the internal standard. Based on the results it can be concluded that the PT was successfully organized. Despite the coronavirus pandemic that occurred during the PT i, the number of participants was satisfactory in order to conclude the third edition of the PT.

Details of the z-score values for each laboratory are given in Tables 19, 20, 21, 22, 23 and 24 with the analytical technique used for each substance.

Table 19. AZOXYSTROBIN Sample PPP01: summary results (ITPT2020)

| ID Lab | Analytical technique | Two day average ¹ | RPD ¹ | Modified z- score ² | Outlier ² |
|----------------------------------|----------------------|------------------------------|------------------|--------------------------------|----------------------|
| 1 | GC-MS | 1.32 | 3.93 | -0.19 | no |
| 3 | HPLC-PDA | 1.41 | 3.97 | 3.15 | no |
| 4 | HPLC-MS/MS QQQ | 1.28 | 1.56 | -1.80 | no |
| 6 | HPLC-DAD | 1.65 | 1.21 | 12.07 | no |
| 9 | HPLC-UV | 1.31 | -1.53 | -0.68 | no |
| 10 | GC-FID | 1.33 | 0 | 0.08 | no |
| 11 | HPLC-DAD | 1.34 | -5.97 | 0.45 | no |
| 12 | HPLC-DAD | 1.33 | -1.5 | 0.08 | no |
| 13 | HPLC-DAD | 1.33 | -1.5 | 0.08 | no |
| 14 | HPLC-UVD | 1.21 | -2.49 | -4.61 | no |
| 15 | GC-FID | 1.32 | -7.58 | -3.30 | no |
| 16 | GC-FID | 1.31 | 2.30 | -0.86 | no |
| 17 | HPLC-UV | 1.26 | 2.39 | -2.74 | no |
| 18 | GC-FID | 1.24 | 1.61 | -3.30 | no |
| 19 | HPLC-UV | 1.66 | 1.81 | 12.25 | no |
| 20 | GC-FID | 1.38 | -2.90 | 1.95 | no |
| 21 | HPLC-VWD | 1.33 | -2.26 | -0.11 | no |
| 22 | GC-FID | 1.34 | 5.97 | 0.45 | no |
| 23 | GC-FID | 1.33 | 1.50 | 0.08 | no |
| 24 | GC-FID | 1.33 | 3.61 | 0.00 | no |
| 26 | GC-FID | 1.28 | -7.06 | -1.99 | no |
| Grand Average³ | | 1.35 | | | |
| Total SD | | 0.11 | | | |
| Total Median⁴ | | 1.33 | | | |
| MAD | | 2.64 | | | |
| MAD_E | | 3.91 | | | |

¹ Average yield and Relative Percent Difference between the two-day determinations per laboratory.

² An outlier is flagged when the modified z-score falls outside the range of $-3.5 \leq Zi \leq 3.5$; see Glossary.

³ Grand average, standard deviation and median.

⁴ Median Absolute Deviation Robust estimate of standard deviation; see Glossary for calculations.

Table 20. EPOXICONAZOLE Sample PPP02: summary results (ITPT2020)

| ID Lab | Analytical technique | Two day average¹ | RPD¹ | Modified z-score² | Outlier² |
|----------------------------------|-----------------------------|------------------------------------|------------------------|-------------------------------------|----------------------------|
| 1 | HPLC-DAD | 6.07 | 2.21 | 0.75 | no |
| 3 | HPLC-PDA | 5.99 | -0.48 | -0.17 | no |
| 4 | HPLC-MS/MS | 6.43 | -1.40 | 4.93 | yes |
| 9 | HPLC-UV | 5.87 | -1.88 | -1.64 | no |
| 10 | HPLC-DAD | 6.43 | -6.38 | 4.93 | yes |
| 11 | HPLC-DAD | 5.86 | 2.22 | -1.76 | no |
| 12 | HPLC-DAD | 6.01 | -2.16 | 0 | no |
| 13 | GC-FID | 5.96 | -1.59 | -0.55 | no |
| 14 | HPLC-UV | 6.00 | -0.67 | -0.06 | no |
| 15 | GC-FID | 6.13 | 0 | 1.47 | no |
| 16 | HPLC-DAD | 6.01 | 0.17 | 0 | no |
| 17 | HPLC-DAD | 5.93 | -0.51 | -0.90 | no |
| 18 | GC-FID | 5.95 | -1.01 | -0.65 | no |
| 20 | HPLC-PDA | 6.08 | 3.79 | 0.82 | no |
| 21 | HPLC-VWD | 6.02 | 0.66 | 0.18 | no |
| 22 | UHPLC-DAD | 6.00 | -0.17 | -0.12 | no |
| 23 | GC-FID | 6.01 | -1.17 | 0 | no |
| 25 | HPLC-DAD | 5.95 | -1.51 | -0.70 | no |
| 26 | GC-FID | 6.1 | 0.82 | 1.06 | no |
| Grand Average³ | | 6.04 | | | |
| Total SD | | 0.16 | | | |
| Total Median⁴ | | 6.01 | | | |
| MAD | | 0.01 | | | |
| MAD_E | | 0.09 | | | |

¹ Average yield and Relative Percent Difference between the two-day determinations per laboratory.

² An outlier is flagged when the modified z-score falls outside the range of $-3.5 \leq Z_i \leq 3.5$; see Glossary.

³ Grand average, standard deviation and median.

⁴ Median Absolute Deviation Robust estimate of standard deviation; see Glossary for calculations.

Table 21. FLUDIOXONIL sample PPP03: summary results (ITPT2020)

| ID Lab | Analytical technique | Two day average¹ | RPD¹ | Modified z-score² | Outlier² |
|----------------------------------|-----------------------------|------------------------------------|------------------------|-------------------------------------|----------------------------|
| 1 | GC-MS | 3.38 | -8.00 | 0.82 | no |
| 3 | HPLC-PDA | 3.34 | 0.75 | -0.10 | no |
| 4 | HPLC-MS/MS | 3.35 | -11.34 | 0.21 | no |
| 6 | HPLC-DAD | 4.15 | 8.19 | 18.19 | yes |
| 9 | HPLC-UV | 3.33 | 1.20 | -0.24 | no |
| 10 | HPLC-DAD | 3.4 | -1.76 | 1.33 | no |
| 11 | HPLC-DAD | 3.38 | -6.22 | 0.77 | no |
| 12 | HPLC-DAD | 3.31 | -0.30 | -0.80 | no |
| 13 | HPLC-DAD | 3.36 | -0.48 | 0.48 | no |
| 14 | HPLC-UV | 3.25 | -0.31 | -2.15 | no |
| 15 | GC-FID | 3.35 | 8.67 | 0.10 | no |
| 16 | HPLC-DAD | 3.35 | -0.60 | 0.21 | no |
| 17 | HPLC-DAD | 3.32 | -0.60 | -0.47 | no |
| 18 | GC-FID | 3.32 | -0.90 | -0.58 | no |
| 19 | HPLC-UV | 3.32 | 1.51 | -0.58 | no |
| 20 | GC-FID | 3.33 | 1.20 | -0.24 | no |
| 21 | HPLC-VWD | 3.32 | 0.30 | -0.58 | no |
| 22 | HPLC-DAD | 3.39 | 0.30 | 0.99 | no |
| 23 | HPLC-DAD | 3.12 | -0.96 | -5.08 | yes |
| 26 | GC-FID | 3.44 | -2.62 | 2.12 | no |
| Grand Average³ | | 3.37 | | | |
| Total SD | | 0.21 | | | |
| Total Median⁴ | | 3.34 | | | |
| MAD | | 0.03 | | | |
| MAD_E | | 0 | | | |

¹ Average yield and Relative Percent Difference between the two-day determinations per laboratory.² An outlier is flagged when the modified z-score falls outside the range of $-3.5 \leq Z_i \leq 3.5$; see Glossary.³ Grand average, standard deviation and median.⁴ Median Absolute Deviation Robust estimate of standard deviation; see Glossary for calculations.

Table 22. METALAXYL-M sample PPP04: summary results (ITPT2020)

| ID Lab | Analytical technique | Two day average ¹ | RPD ¹ | Modified z-score ² | Outlier ² |
|----------------------------------|----------------------|------------------------------|------------------|-------------------------------|----------------------|
| 1 | GC-MS | 2.75 | 3.53 | 0.72 | no |
| 4 | HPLC-MS/MS | 2.78 | -2.88 | 1.13 | no |
| 6 | HPLC-DAD | 3.37 | 1.49 | 8.47 | yes |
| 9 | HPLC-UV | 2.67 | 0 | -0.25 | no |
| 10 | HPLC-DAD | 2.75 | -1.45 | 0.75 | no |
| 11 | HPLC-DAD | 2.76 | -7.62 | 0.82 | no |
| 12 | HPLC-DAD | 2.74 | 0.37 | 0.56 | no |
| 13 | HPLC-DAD | 2.58 | -2.25 | -1.36 | no |
| 14 | HPLC-UV | 2.66 | 0.38 | -0.44 | no |
| 15 | GC-FID | 2.56 | 1.96 | -1.69 | no |
| 16 | GC-FID | 2.64 | 0.38 | -0.69 | no |
| 17 | HPLC-DAD | 2.6 | -1.93 | -1.19 | no |
| 18 | GC-FID | 2.72 | 0 | 0.38 | no |
| 19 | HPLC-UV | 2.35 | 4.26 | -4.27 | yes |
| 20 | GC-FID | 2.72 | 2.58 | 0.31 | no |
| 21 | HPLC-VWD | 2.67 | 0.75 | -0.25 | no |
| 22 | GC-FID | 2.69 | 6.33 | -0.06 | no |
| 23 | GC-FID | 2.8 | -1.79 | 1.32 | no |
| 24 | GC-FID | 2.67 | -0.41 | -0.26 | no |
| 26 | HPLC-DAD | 2.7 | 0.37 | 0.06 | no |
| Grand Average³ | | 2.71 | | | |
| Total SD | | 0 | | | |
| Total Median⁴ | | 2.69 | | | |
| MAD | | 0.05 | | | |
| MAD_E | | 0.08 | | | |

¹ Average yield and Relative Percent Difference between the two-day determinations per laboratory.² An outlier is flagged when the modified z-score falls outside the range of $-3.5 \leq Z_i \leq 3.5$; see Glossary.³ Grand average, standard deviation and median.⁴ Median Absolute Deviation Robust estimate of standard deviation; see Glossary for calculations.

Table 23. PYRACLOSTROBIN sample PPP05: summary results (ITPT2020)

| ID Lab | Analytical technique | Two day average ¹ | RPD ¹ | Modified z-score ² | Outlier ² |
|----------------------------------|----------------------|------------------------------|------------------|-------------------------------|----------------------|
| 1 | HPLC-DAD | 8.12 | 2.79 | -0.25 | no |
| 3 | HPLC-PDA | 8.06 | 1.95 | -0.64 | no |
| 4 | HPLC-MS/MS | 7.83 | -10.61 | -2.02 | no |
| 9 | HPLC-UV | 7.94 | -1.13 | -1.37 | no |
| 10 | HPLC-DAD | 8.52 | -0.47 | 2.12 | no |
| 11 | HPLC-DAD | 7.84 | 1.66 | -1.96 | no |
| 12 | HPLC-DAD | 8.15 | 0 | -0.09 | no |
| 13 | HPLC-DAD | 8.17 | 1.2 | 0.03 | no |
| 14 | HPLC-UV | 8.34 | -2.76 | 1.02 | no |
| 15 | HPLC-PDA | 8.34 | 1.2 | 1.05 | no |
| 16 | HPLC-DAD | 8.14 | -0.49 | -0.15 | no |
| 17 | HPLC-DAD | 7.97 | -0.50 | -1.07 | no |
| 18 | HPLC-DAD | 8.66 | -1.04 | 2.92 | no |
| 19 | HPLC-UV | 8.05 | 2.36 | -0.71 | no |
| 20 | HPLC-DAD | 8.19 | 1.47 | 0.15 | no |
| 21 | HPLC-VWD | 8.22 | 1.10 | 0.30 | no |
| 22 | HPLC-DAD | 8.33 | -1.92 | 0.99 | no |
| 23 | HPLC-DAD | 7.63 | -3.93 | -3.18 | no |
| 24 | HPLC-UV | 8.25 | -100 | 0.51 | no |
| 25 | HPLC-DAD | 8.16 | -0.98 | -0.03 | no |
| 26 | HPLC-DAD | 8.22 | -0.49 | 0.33 | no |
| Grand Average³ | | 8.14 | | | |
| Total SD | | 0.26 | | | |
| Total Median⁴ | | 8.16 | | | |
| MAD | | 0.12 | | | |
| MAD_E | | 0.18 | | | |

¹ Average yield and Relative Percent Difference between the two-day determinations per laboratory.² An outlier is flagged when the modified z-score falls outside the range of $-3.5 \leq Z_i \leq 3.5$; see Glossary.³ Grand average, standard deviation and median.⁴ Median Absolute Deviation Robust estimate of standard deviation; see Glossary for calculations.

Table 24. THIABENDAZOLE sample PPP06: summary results (ITPT2020)

| ID Lab | Analytical technique | Two day average¹ | RPD¹ | Modified z-score² | Outlier² |
|----------------------------------|-----------------------------|------------------------------------|------------------------|-------------------------------------|----------------------------|
| 1 | HPLC-DAD | 26.71 | 0.15 | 0.19 | no |
| 3 | HPLC-MS/MS | 27.29 | 0.11 | 1.05 | no |
| 6 | HPLC-DAD | 30.20 | 0 | 5.42 | yes |
| 10 | HPLC-DAD | 26.59 | 0.56 | 0 | no |
| 11 | HPLC-DAD | 24.20 | -100 | -3.57 | yes |
| 13 | HPLC-DAD | 25.93 | -0.87 | -0.99 | no |
| 14 | HPLC-UV | 25.90 | -0.46 | -1.03 | no |
| 15 | HPLC-PDA | 26.28 | 2.13 | -0.46 | no |
| 16 | HPLC-DAD | 26.62 | -0.19 | 0.04 | no |
| 17 | HPLC-DAD | 26.76 | 0.86 | 0.25 | no |
| 18 | HPLC-DAD | 26.41 | -0.04 | -0.27 | no |
| 19 | HPLC-UV | 27.15 | -3.31 | 0.85 | no |
| 20 | GC-FID | 26.84 | 2.05 | 0.37 | no |
| 21 | HPLC-VWD | 26.64 | -0.45 | 0.08 | no |
| 22 | HPLC-DAD | 25.87 | 1.82 | -1.08 | no |
| 23 | HPLC-DAD | 25.93 | 0.31 | -0.98 | no |
| 26 | HPLC-DAD | 26.14 | 0.65 | -0.67 | no |
| Grand Average³ | | 26.63 | | | |
| Total SD | | 1.11 | | | |
| Total Median⁴ | | 26.59 | | | |
| MAD | | 0.45 | | | |
| MAD_E | | 0.67 | | | |

¹ Average yield and Relative Percent Difference between the two-day determinations per laboratory.² An outlier is flagged when the modified z-score falls outside the range of $-3.5 \leq Z_i \leq 3.5$; see Glossary.³ Grand average, standard deviation and median.⁴ Median Absolute Deviation Robust estimate of standard deviation; see Glossary for calculations.

Table 25, 26, 27, 28, 29 and 30 report the information on analytical methods used for each substance and each laboratory.

Table 25. AZOXYSTROBIN representative method for the determination (ITPT2020)

| ID | Reference Lab method | Internal standard | Extractants | Sample preparation | Injection volume | Column T° | Detector | Column |
|----|----------------------------|---|--------------------------|--|---------------------|-----------------|--------------------------------|--|
| 1 | In-house method | N/A | Acetone | In contact for 24 hours | 2 µL | Gradient | MS | Equity5, 30 m*0.25 mm*0.25 µm |
| 3 | In-house method | N/A | MetOH/Water 90:10 | Dissolve sample in 5 mL of water, fill to mark with MetOH, diluted with MetOH and filtered with 0.45 | 10µL | 25°C | PDA | Synergy 4 µm Hydro-RP 80 A, 4 µm, 150 mm*2mm |
| 4 | In-house method | Triphenyl- phosphate | Acetone | Sonicate for 10 min | 10 µL | 40°C | MS/MS QQQ | Ascentis Express RP-AMIDE 2.7 µm, 150 mm*2.1 mm |
| 6 | In-house method | N/A | ACN | Sonicate for 15 min dilute and filter through 0.45 µm nylon | 10 µL | 35°C | DAD | Agilent Zorbax Eclipse XDB C8 5 µm, 150 mm*4.6 mm |
| 9 | In-house method | N/A | ACN | Sonicate for 5 min | 2 µL | 30°C | UV | Xterra RP18 150 mm* 2.1mm* 3.5 µm |
| 10 | CIPAC 571 | 3-(2-pyridyl)- 5,6 diphenyl- 1,2,4-triazine | Acetone | Ultrasonication 15 min, dilute and filter with 0.45 µm PTFE | 1 µL | 280°C | FID | CP Sil 8 CB-MS 30 m* 0.25 mm* 0.5 µm |
| 11 | In-house method | N/A | Water/THF (50:50 v/v) | Sonicate for 15 min, shake for homogenization | 10 µL | 35°C | DAD | Nucleodur C18 Gravity 5 µm* 250mm* 3 mm |
| 12 | In-house method | N/A | ACN | Dissolution in 50 mL ACN, 15 min sonication, filtration through 0.45 µm regenerated cellulose disk | 2 µL | 30°C | DAD | LiChrospher 100 RP18 5 µm* 250 mm* 4.0 mm |
| 13 | In-house method | N/A | ACN | Dilute the mg in 50 mL volumetric flasks with ACN | 10 µL | 35°C | DAD | Nucleodur C18 Gravity 5 µm* 150 mm* 4.6 mm |
| 14 | In-house method | N/A | ACN | Sonicate for 15 min | 5 µL | Ambient | Dionex UVD 170S | Zorbax SB-C18 5 µm 4.6 mm* 250 mm |
| 15 | In-house method | N/A | Ethyl acetate | Weigh, sonicate approx. 10 min allow to cool to room temp, make up to volume, filter | 0.2 µL | Gradient FID | HP 5 MS 30 m* 0.25 mm* 0.25 µm | <i>to be followed</i> |

continues

| ID | Reference Lab method | Internal standard | Extractants | Sample preparation | Injection Column volume T° | Detector Column |
|----|--|---|-------------------|--|----------------------------|--|
| 16 | In-house method | N/A | Acetone | Sonicate for 5 min | 1 µL | Gradient FID HP 5MS 30 m* 250 mm* 0.25 µm |
| 17 | In-house method | N/A | Water: MetOH 5/95 | For sample dispersing with water, sonicated for 1 min, then fill with MetOH, filter on 0.2 µm nylon disk | 1µL 40°C | DAD Phenomenex Kinetex C18 2.6 µm* 100 mm* 4.6 mm |
| 18 | CIPAC 571 | 3-(2-pyridyl)- 5, 6-diphenyl-1,2,4-triazine | Acetone | Sonicate for 30 min | 1µL | Gradient FID CP-Sil 13 CB 25 m* 0.32mm* 0.20 µm |
| 19 | In-house method | N/A | MetOH | N/A | 1 µL | Ambient UV Spherisorb S5 ODS2 C18 5 µm* 250 mm* 4.6 mm |
| 20 | Manufacturer's method | Diphenyl phthalate | Acetone | Test sample/SI to solution, sonicate for 20 min, filter through 0.2 µm nylon disk | 1µL | Gradient FID Agilent DB 5MS 30 m* 0.25 mm* 0.25 µm |
| 21 | In-house method | N/A | Acetonitrile | Sonication for 10 min, filtration through nylon 0.45 µm disk | 5 µL 30°C | VWD Zorbax Eclipse XDB C18 5 µm* 4.6 mm* 150 mm |
| 22 | In-house method | Dicyclohexyl phthalate | Acetone | Sonicate for 8 min, filter through 0.45 µm PTFE syringe filter | 1 µL | Gradient FID TG-5MS 30 m* 0.25 mm* 0.26 µm |
| 23 | CIPAC 571 | 3-(2-pyridyl)- 5, 6-diphenyl-1,2,4-triazine | N/A | N/A | 1 µL | Gradient FID Thermo 30 m* 0.25 mm* 250 µm |
| 24 | In-house method | Diocetyl phthalate n | Tetrahydrofuran | Sonicate for 20 min, centrifuge to separate insoluble material | 1 µL | Gradient FID CP Sil 13 CB 30 m* 0.25 mm* 250 µm |
| 26 | Manufacturer's Dipentyl phthalate method | Acetone | | Sonicate for 10 min, filtered with 0.45 µm PTFE disk | 1 µL | Gradient FID DB-10.25 µm, 30 m* 0.25 mm |

Table 26. EPOXICONAZOLE: representative method for the determination (IPTT2020)

| ID | Reference Lab method | Internal standard | Extractants | Sample preparation | Injection volume | Column T° | Detector | Column |
|----|----------------------|-------------------|-------------------------|---|------------------|-----------|------------|--|
| 1 | In-house method | N/A | ACN | Sonicate for 20 min, filtered 0.45 µm PTFE disk | 5 µL | 40°C | DAD | Zorbax ODS C18 5 µm*, 150 mm* 4.6 mm |
| 3 | In-house method | N/A | MetOH: Water 90:10 | Dissolve sample in 5 mL of water. Fill to mark with MetOH, diluted with MetOH and filter with 0.45 µm | 10 µL | 25°C | PDA | Synergy 4 µm Hydro-RP 80 Å, 4 µm, 150 mm* 2 mm |
| 4 | In-house method | N/A | Triphenyl phosphate | Sonicate for 10 min | 10 µL | 40°C | MS/MS QQQ | Ascentis Express RP-AMIDE 2.7 µm, 150 mm* 2.1 mm |
| 9 | In-house method | N/A | ACN | Sonicate for 5 min | 2 µL | 30°C | UV | Xterra RP18 150 mm* 2.1 mm* |
| 10 | In-house method | N/A | Water: ACN 10:90 | Ultrasonication 15 min, dilute 10 µL and filter with 0.45 µm PTFE | 10 µL | 30°C | DAD | Kintex C18 5 µm, 150 mm* 4.6 mm |
| 11 | In-house method | N/A | Acid Water: THF (50:50) | Sonicate for 15 min, shake for homogenization, filter through 0.2 µm PP disk | 10 µL | 35°C | DAD | Nucleodur C18 5 µm, 250 mm* 3 mm |
| 12 | In-house method | N/A | MetOH | Dissolution in 50 mL MetOH, 15 min sonication, filtration through 0.45 µm regenerated cellulose disk | 2 µL | 30°C | DAD | LiChrospher 100 RP18, 5 µm* 250 mm*4.0 mm |
| 13 | CIPAC 609 | N/A | THF | Follow the method | 1 µL | 250°C | FID | DB-130 m 0.53 mm* 1.5 µm |
| 14 | In-house method | N/A | ACN | Sonicate for 15 min | 5 µL | Ambient | Dionex UVD | Zorbax SB-C18, 5 µm* 4.6 mm* 250 mm |
| 15 | In-house method | N/A | Ethyl Acetate | Weigh, sonicate approx 10 min, allow to cool to room temp, make up to volume, filter | 0.2 µL | Gradient | FID | HP 5 MS, 30 m* 0.25 mm* 0.25 µm |
| 16 | In-house method | N/A | ACN: Water 6:4 | Sonicate for 1 min | 3 µL | 25°C | DAD | Altima C18, 5 µm, 250 mm* 4.6 mm |

to be followed

continues

| ID | Reference Lab method | Internal standard | Extractants | Sample preparation | Injection Column volume T° | Detector Column |
|----|-----------------------|----------------------|--------------------------|---|----------------------------|--|
| 17 | In-house method | N/A | ACN; Water 95:5 | Sonicate for 1 min filtered on 0.2 µm nylon disk | 1 µL | 30°C DAD Phenomenex Kinetex C18 5 µm 100 mm* 4.6 mm |
| 18 | CIPAC 609 | Tetraphenyl ethene | THF | Sonicate for 15 min | 1 µL | 230°C FID DB-1 30 m 0.32 mm* 0.25 µm |
| 20 | Manufacturer's method | N/A | Water: ACN 40:60 | Solvent extraction, sonicate 20 min, filtered through 0.2 µm nylon disk | 1 µL | 40°C PDA Phenomenex Luna C18 5 µm, 4.6 mm* 150 mm |
| 21 | In-house method | N/A | ACN | Sonicate for 10 min, filter through 0.45 µm nylon disk | 5 µL | 30°C VWD Zorbax Eclipse XDB-C18 5 µm* 150 mm* 4.6 mm |
| 22 | In-house method | N/A | ACN | Sonicate for 8 min filter through 0.22 µm PTFE syringe filter | 0.5 µL | 25°C DAD Phenomenex Kinetex 2.6 µm, 2.1 mm* 100 mm |
| 23 | In-house method | N/A | N/A | N/A | 1 µL | 230°C FID Thermo 30 m* 0.25 mm* 0.25 µm |
| 25 | In-house method | N/A | MetOH: Acetic Acid 73:27 | Shake the sample for 3 min, dilute and filter 0.45 µm PTFE filter | 5 µL | 30°C DAD Poroshell 120 EC-C18 2.7 µm 4.6 mm* 50 mm |
| 26 | CIPAC 609 | Di N Butyl phthalate | THF | Follow the method | 1 µL | Gradient FID DB-1 0.25 µm 30 m* 0.25 mm |

Table 27. FLUDIOXONIL: representative method for the determination (ITPT2020)

| ID | Reference Lab method | Internal standard | Extractants | Sample preparation | Injection volume | Column T° | Detector | Column |
|----|----------------------|---------------------|--------------------------|---|------------------|-----------|--|------------------------------------|
| 1 | In-house method | N/A | Acetone | In contact for 24 Hours | 2 µL | Gradient | MS | Equity 5, 30 m* 0.25 mm* 0.25 µm |
| 3 | In-house method | N/A | MeOH: Water 90:10 | Dissolve sample in 5 mL of water, fill to mark with MetOH, diluted with MetOH and filter with 0.45 µm | 10 µL | 25°C | PDA | Synergy 4 µm Hydro-RP 80 A 4 µm* |
| 4 | In-house method | Triphenyl phosphate | Acetone | Sonicate for 10 µm | 10 µL | 40°C | MS/MS QQQ | Ascentis Express RP-AMIDE 2.7 µm |
| 6 | In-house method | N/A | ACN | Sonicate for 15 min dilute and filter through 0.45 µm nylon disk | 10 µL | 35°C | DAD | Agilent Zorbax Eclipse XDB C8 5 µm |
| 9 | In-house method | N/A | ACN | Sonicate for 5 min | 2 µL | 30°C | UV | Xterra RP18 150 mm* 2.1 mm* 3.5 µm |
| 10 | In-house method | N/A | Water: ACN 10:90 | Ultrasonication 15 min dilute and filter with 0.45 µm PTFE | 10 µL | 30°C | DAD | Kintex C18 µm 150 mm* 4.6 mm |
| 11 | In-house method | N/A | Acid VWater: THF (50:50) | Sonicate for 15 min shake for 10 µL 0.2 µm PP disk | 35°C | DAD | Nucleodur C18 5 µm 250 mm* 250 mm* 3mm | LiChrospher 100 RP18, 5 µm* 250 |
| 12 | In-house method | N/A | ACN | Dissolution in 50 mL ACN 15 min sonication filtration through 0.45 µm regenerated cellulose disk | 3 µL | 30°C | DAD | |
| 13 | In-house method | N/A | ACN | Diluted and fill to mark | 10 µL | 35°C | DAD | Nucleodur C18 5 µm, 250 mm* 3 mm |
| 14 | In-house method | N/A | ACN | Sonicate for 15 min | 5 µL | Ambient | Dionex UVD | Zorbax SB-C18 5 µm* 4.6 mm* 250 mm |
| 15 | In-house method | N/A | Ethyl Acetate | Weigh sonicate approx 10 min allow to cool to room temp make up to volume filter | 0.2 µL | Gradient | FID | HP 5 MS 30 m* 0.25 mm* 0.25 µm |
| 16 | In-house method | N/A | ACN: Water 6:4 | Sonicate for 1 min | 6 µL | 25°C | DAD | Altima C18 5 µm 250 mm* 4.6 mm |

to be followed

| ID | Reference Lab method | Internal standard | Extractants | Sample preparation | Injection volume | Column T° | Detector | Column |
|-----------|--|--------------------------|------------------------|--|-------------------------|------------------|-----------------|--|
| 17 | In-house method | N/A | Water: MetOH 5:95 | Sonicate for 1 min fill to mark with MetOH filtered with 0.2 µm nylon disk | 1 µL | 40°C | DAD | Phenomenex Kinetex C18 2.6 µm 100 mm* 4.6 mm |
| 18 | In-house method | Dibutyl phthalate | MetOH: Toluene (50:50) | Sonicate for 15 min | 1 µL | 205°C | FID | DB-17 30 m 0.25 mm* 0.5 µm |
| 19 | In-house method | N/A | MetOH | N/A | 20 µL | Ambient | UV | Spherisorb S5 ODS2 C18 5 µm* 250 mm* 4.6 mm |
| 20 | Manufacturer's Diphenyl-phthalate method | | Acetone | Solvent extraction sonicate 20 min filtered through 0.2 µm nylon disk | 1 µL | Gradient | FID | Agilent DB 5 MS 30 m* 0.25 mm* 0.25 µm |
| 21 | In-house method | N/A | ACN | Sonicate for 10 min Filter through 0.45 µm nylon disk | 5 µL | 30°C | VWD | Zorbax Eclipse XDB-C18 5 µm* 150 mm 4.6 mm |
| 22 | In-house method | N/A | ACN | Sonicate for 8 min filter through 0.22 µm PTFE syringe filter | 2 µL | 30°C | DAD | Zorbax SB-C18 5 µm 4.6 mm* 250 mm |
| 23 | In-house method | N/A | N/A | N/A | 10 µL | N/A | DAD | Zorbax Eclipse C18 5 µm* 250 mm* 4.6 mm |
| 26 | Manufacturer's Dipentyl phthalate method | | Acetone | Sonicate for 10 min Filter through 0.45 µm PTFE disk | 1 µL | Gradient | FID | DB-1 0.25 µm 30 m* 0.25 mm |

Table 28. METALAXYL-M: representative method for the determination (ITPT2020)

| ID | Reference Lab method | Internal standard | Extractants | Sample preparation | Injection volume | Column T° | Detector | Column |
|----|----------------------|---------------------|-------------------------|--|------------------|-----------|------------|---|
| 1 | In-house method | N/A | Acetone | In contact for 24 hours | 2 µL | 250°C | MS | Equity 5 30 m* 0.25 mm* 0.25 µm |
| 4 | In-house method | Triphenyl phosphate | ACN | Sonicate for 10 min | 10 µL | 40°C | MS/MS QQ | Ascentis Express RP-AMIDE 2.7 µm 150mm* 2.1 mm |
| 6 | In-house method | N/A | ACN | Sonicate for 15 min dilute and filter through 0.45 µm nylon disk | 10 µL | 35°C | DAD | Agilent Zorbax Eclipse XDB C8 5 µm 150 mm* 4.6 mm |
| 9 | In-house method | N/A | ACN | Sonicate for 5 min | 2 µL | 30°C | UV | Xterra RP18 150 mm* 2.1 mm* 3.5 µm |
| 10 | In-house method | N/A | Water: ACN 50:50 | Ultrasonication 15 min dilute and filter with 0.45 µm PTFE | 10 µL | 30°C | DAD | Kintex C18 5 µm 150 mm* 4.6 mm |
| 11 | In-house method | N/A | Acid Water: THF (50:50) | Sonicate for 15 min shake for 10 µL homogenization filter through 0.2 µm PP disk | 10 µL | 35°C | DAD | Nucleodur C18 5 µm 250 mm* 3 mm |
| 12 | In-house method | N/A | ACN | Dissolution in 50 mL ACN 15 min sonication filtration through 0.45 µm regenerated cellulose disk | 2 µL | 30°C | DAD | LiChrospher 100 RP18 5 µm* 250mm* 4.0 mm |
| 13 | In-house method | N/A | ACN | Dilution and fill to mark | 10 µL | 35°C | DAD | Nucleodur C18 5 µm 250 mm* 3 mm |
| 14 | In-house method | N/A | ACN | Sonicate for 15 min | 5 µL | Ambient | Dionex UVD | Zorbax SB-C18, 5 µm* 4.6 mm* 250 mm |
| 15 | In-house method | N/A | Ethyl Acetate | Weigh sonicate approx. 10 min allow to cool to room temp make up to volume filter | 0.2 µL | Gradient | FID | HP 5 MS 30 m* 0.25 mm* 0.25 µm |
| 16 | In-house method | N/A | ACN: Water 6:4 | Sonicate for 5 min | 1 µL | Gradient | FID | HP-5MS 30 m 250 mm 0.25 µm |
| 17 | In-house method | N/A | Water:MetOH 5:95 | Sonicate for 1 min fill to mark with MetOH filtered with 0.2 µm nylon disk | 1 µL | 40°C | DAD | Phenomenex Kinetex C18 2.6 µm 100 mm* 4.6 mm |

to be followed

continues

| ID | Reference Lab method | Internal standard | Extractants | Sample preparation | Injection volume | Column T° | Detector | Column |
|----|--|-------------------|---------------------------------|---|------------------|-----------|---|---|
| 18 | In-house method | Dibutyl phthalate | MetOH: Toluene (50:50) | Sonicate for 15 min | 1 µL | 205°C | FID | DB 17 30 m 0.25 mm* 0.5 µm |
| 19 | In-house method | N/A | MetOH | N/A | 20 µL | Ambient | UV | Spherisorb S5 ODS2 C18 5 µm* 250 mm* 4.6 mm |
| 20 | Manufacturer's Diphenil-phthalate method | | Acetone | Solvent extraction sonicate 20 min filtered through 0.2 µm nylon disk | 1 µL | Gradient | FID | Agilent DB 5 MS 30m* 0.25 mm* 0.25 µm |
| 21 | In-house method | N/A | ACN | Sonicate for 10 min filter through 5 µL 0.45 µm nylon disk | 30 °C | VWD | Zorbax Eclipse XDB-C18 5 µm* 150 mm* 4.6 mm | |
| 22 | In-house method | | Dicyclohexyl- Acetone phthalate | Sonicate for 8 min filter through 0.22 µm PTFE syringe filter | 1 µL | Gradient | FID | TG-5 MS 0.25 µm 0.25 mm* 30 m |
| 23 | CIPAC 365 | Methyl Stearate | N/A | | 1 µL | 225°C | FID | Thermo 30 m* 0.25 mm* 250 µm |
| 24 | In-house method | Diethyl phthalate | THF | Sonicate for 20 min centrifuge to separate insoluble material | 1 µL | Gradient | FID | CP Sil 13 CB 30 m* 0.25 mm* 250 µm |
| 26 | Manufacturer's N/A method | | ACN: Water 5:5 | Sonicate for 15 min dilute and filter through 0.45 µm nylon disk | 5 µL | 25°C | DAD | Chiracel OD-RH 5 µm 150 mm* 2.1 mm |

Table 29. PYRACLOSTROBIN: representative method for the determination (ITPT2020)

| ID | Reference Lab method | Internal standard | Extractants | Sample preparation | Injection volume | Column T° | Detector | Column |
|----|----------------------|-------------------|-----------------------------|---|------------------|-----------|------------|---|
| 1 | In-house method | N/A | ACN | Sonicate for 20 min filtered with 0.45 µm | 5 µL | 40 °C | DAD | Zorbax ODS C18 5 µm 150 mm* 4.6 mm |
| 3 | In-house method | N/A | MetOH: Water 90:10 | Dissolve sample in 5 mL of water fill to mark with MetOH diluted with MetOH and filter with 0.45 µm | 10 µL | 25°C | PDA | Synergy 4 µm Hydro-RP 80 A 4 µm* 150 mm* 2 mm |
| 4 | In-house method | N/A | Triphenyl-phosphate | Sonicate for 10 min | 10 µL | 40°C | MS/MS QQQ | Ascentis Express RP-AMIDE 2.7 µm |
| 9 | In-house method | N/A | Acetone | Sonicate for 10 min | 2 µL | 30°C | UV | Xterra RP18 150 mm* 2.1 mm* 3.5 µm |
| 10 | In-house method | N/A | Water: ACN 10:90 | Ultrasonication 15 min dilute and filter with 0.45 µm PTFE | 10 µL | 30°C | DAD | Kintex C18 5 µm 150 mm* 4.6 mm |
| 11 | In-house method | N/A | Acid Water: THF (50:50) | Sonicate for 15 min shake for homogenization filter through 0.2 µm PP disk | 10 µL | 35°C | DAD | Nucleodur C18 5 µm 250 mm* 3 mm |
| 12 | In-house method | N/A | ACN/ 0.4% Acetic Acid 75:25 | Dissolution in 50 mL ACN/ 0.4% Acetic Acid 75:25 15 min sonication | 5 µL | 30°C | DAD | LiChrospher 100 RP18 5 µm* 250mm* 4.0 mm |
| 13 | CIPAC 657 | N/A | Water: ACN 25:75 | Follow the method | 5 µL | 40°C | DAD | Phenomenex Luna C18 (2) 250 4.6 mm* 5 µm |
| 14 | In-house method | N/A | ACN | Sonicate for 15 min | 5 µL | Ambient | Dionex UVD | Zorbax SB-C18, 5 µm* 4.6 mm* 250 mm |
| 15 | In-house method | N/A | ACN | Weigh sonicate approx. 10 min allow to cool to room temp make up to volume filter | 5 µL | 25 °C | PDA | Phenomenex Kinetex C18 2.6 µm 100 mm* 4.6 mm |
| 16 | In-house method | N/A | ACN: Water 6:4 | Sonicate for 1 min | 3 µL | 25 °C | DAD | Altima C18 5 µm 250 mm* 4.6 mm |
| 17 | In-house method | N/A | ACN: Water 95:5 | Sonicate for 1 min filtered with 0.2 µm nylon disk | 1 µL | 30°C | DAD | Phenomenex Kinetex 5 µm* 4.6 mm* 100 mm |

to be followed

continues

| ID | Reference Lab method | Internal standard | Extractants | Sample preparation | Injection volume | Column T° | Detector | Column |
|----|-----------------------|-------------------|--------------------------|---|------------------|-----------|----------|---|
| 18 | CIPAC 657 | N/A | ACN: Water 75:25 | Sonicate for 15 min | 5 µL | 25°C | DAD | Zorbax Eclipse XDB-C18 5 µm* 250 mm* 4.6 mm |
| 19 | In-house method | N/A | MetOH | N/A | 5 µL | Ambient | UV | Spherisorb S5 ODS2 C18 5 µm* 250 mm* 4.6 mm |
| 20 | Manufacturer's method | N/A | Water: CAN 40:60 | Solvent extraction sonicate 20 min filtered through 0.2 µm nylon disk | 1 µL | 40 °C | PDA | Phomenex Luna C18 5 µm 4.6 mm* 150 mm |
| 21 | In-house method | N/A | ACN | Sonicate for 10 min filter through 0.45 µm nylon disk | 5 µL | 30°C | VWD | Zorbax Eclipse XDB-C18 5 µm* 150 mm* 4.6 mm |
| 22 | In-house method | N/A | ACN | Sonicate for 8 min filter through 0.22 µm PTFE syringe filter | 0.5 µL | 45 °C | DAD | Phomenex Kinetex 2.6 µm 2.1 mm* 100 mm |
| 23 | CIPAC 657 | N/A | N/A | N/A | 5 µL | N/A | DAD | Zorbax Eclipse C18 5 µm* 250 mm* 4.6 mm |
| 24 | In-house method | Cyproconazole | MetOH: CAN 10:2 | Sonicate for 10 min centrifuge to separate insoluble material | 1 µL | 25 °C | UV | Eclipse XDB C18 150 m* 4.6 mm* 5 µm |
| 25 | In-house method | N/A | MetOH: Acetic Acid 73:27 | Shake the sample for 3 min dilute and filter 0.45 µm PTFE filter | 5 µL | 30°C | DAD | Poroshell 120 EC-C18 2.7 µm 4.6 mm* 50 mm |
| 26 | CIPAC 657 | N/A | ACN | Follow the method | 5 µL | Ambient | DAD | Zorbax Eclipse C18 5 µm* 250 mm* 4.6 mm |

Table 30. THIABENDAZOLE: representative method for the determination (ITPT2020)

| ID | Reference Lab method | Internal standard | Extractants | Sample preparation | Injection volume | Column T° | Detector | Column |
|----|----------------------|-------------------|-------------------------|---|------------------|-----------|---------------------------------|---|
| 1 | In-house method | N/A | ACN: Water 80:20 | Sonicate for 20 min filtered with 0.45 µm PTFE disk | 40 °C | DAD | Luna 3U C18 3 µm 150 mm* 4.6 mm | |
| 3 | In-house method | N/A | MetOH: Water 90:10 | Dissolve sample in 5 mL of water fill to mark with MetOH diluted with MetOH and filter with 0.45 µm | 10 µL | 25°C | MS/MS | Synergy 4 µm Hydro-RP 80 A 4 µm 150 mm* 2 mm |
| 6 | In-house method | N/A | ACN | Sonicate for 15 min dilute and filter through 0.45 µm nylon disk | 10 µL | 35°C | DAD | Agilent Zorbax Eclipse XDB C8 5 µm 150 mm* 4.6 mm |
| 10 | CIPAC 323 | N/A | Water: MetOH 5:95 | Sonicate for 30 min dilute and filter with 0.45 µm PTFE | 10 µL | 35°C | DAD | Luna C18(2) 100A 5 µm 250 mm* 4.6 mm |
| 11 | In-house method | N/A | Acid Water: THF (50:50) | Sonicate for 15 min shake for homogenization filter through 0.2 µm PP disk | 10 µL | 35°C | DAD | Nucleodur C18 5 µm 250 mm* 3 mm |
| 13 | CIPAC 323 | N/A | MetOH Mobile Phase | Follow the method | 10 µL | 27°C | DAD | Phenomenex Luna C18 (2) 250 4.6 mm* 5 µm |
| 14 | In-house method | N/A | ACN | Sonicate for 15 min | 5 µL | Ambient | Dionex UVD | Zorbax SB-C18 5 µm* 4.6 mm* 250 mm |
| 15 | CIPAC 323 | N/A | ACN | Weigh sonicate approx. 10 min allow to cool to room temp make up to volume filter | 5 µL | 25°C | PDA | Phenomenex Kinetex C18 2.6 µm 100 mm* 4.6 mm |
| 16 | In-house method | N/A | ACN: Water 6:4 | Sonicate for 1 min | 6 µL | 25 °C | DAD | Altima C18 5 µm 250 mm* 4.6 mm |
| 17 | In-house method | N/A | Water: MetOH 5:95 | Sonicate for 1 min fill to mark with MetOH filtered with 0.2 µm nylon disk | 1 µL | 40 °C | DAD | Phenomenex Kinetex C18 2.6 µm 100 mm* 4.6 mm |

to be followed

| <i>continues</i> | ID | Reference Lab method | Internal standard | Extractants | Sample preparation | Injection volume | Column T° | Detector | Column |
|------------------|--|----------------------|-------------------|-------------|--|------------------|-----------|----------|---|
| 18 | CIPAC 323 | N/A | MetOH: Water 95:5 | | Sonicate for 15 min | 10 µL | 25 °C | DAD | Nucleosil 100-5 C18 5 µm* 250 mm* 4.0 mm |
| 19 | In-house method | N/A | MetOH | | N/A | 1 µL | Ambient | UV | Spherisorb S5 ODS2 C18 5 µm* 250 mm* 4.6 mm |
| 20 | Manufacturer's Diphenil phthalate method | | Acetone | | Solvent extraction sonicate for 20 min filtered through 0.2 µm nylon disk | 1 µL | Gradient | FID | Agilent DB 5 MS 30 m* 0.25 mm* 0.25 µm |
| 21 | In-house method | N/A | ACN | | Sonicate for 10 min filter through 0.45 µm nylon disk | 5 µL | 30°C | VWD | Zorbax Eclipse XDB-C18 5 µm* 150 mm* 4.6 mm |
| 22 | CIPAC 323 | N/A | MetOH | | Sonicate for 8 min filter through 0.22 µm PTFE syringe filter | 10 µL | 30°C | DAD | Zorbax SB-C18 5 µm 4.6 mm* 250 mm |
| 23 | CIPAC 323 | N/A | MetOH | | N/A | 10 µL | 25°C | DAD | Agilent C18 250 mm* 4.6 mm* 5 µm |
| 26 | CIPAC 323 | N/A | MetOH | | Follow the method | 10 µL | Ambient | DAD | Zorbax Eclipse C18 5 µm* 250 mm* 4.6 mm |

REFERENCES

- Association of American Pesticide Control Officials. *Pesticide formulations checks sample program.* West Lafayette; AAPCO; 2016.
- ISO/IEC 13528:2015. *Statistical methods for use in proficiency testing by interlaboratory comparison.* Geneva: International Organization for Standardization; 2015
- ISO/IEC 17025:2018. *General requirements for the competence of testing and calibration laboratories.* Geneva: International Organization for Standardization; 2018.
- Rivera CP, Rodríguez RD, Pimentel SH. Horwitz equation as quality benchmark in ISO/IEC 17025 Testing Laboratory. In: *Conference proceedings*; 2011.
- Thompson M, Ellison SLR, Wood R. The International Harmonized Protocol for the Proficiency testing of analytical chemistry laboratories (IUPAC Technical Report). *Pure Appl Chem* 2006;78(1):145-96.

APPENDIX A
The announcement letter

ANNOUNCEMENT/INVITATION ITPT2020

Dear Colleagues,

We herewith cordially invite you to participate in the Italian Proficiency Test on the analysis of PPPs in SL and SE. This exercise is organized by the Italian Laboratory of Istituto Superiore di Sanità (National Institute of Health) – Department of Environment and Health. The ITPT2020 is scheduled to run from 15th January until 30th May 2020.

AIMS

Participation in proficiency tests is part of the QA/QC system of laboratories and provides them with an assessment of their analytical performance as well as a comparison with the performance of other laboratories. The general aim is to help laboratories demonstrate adequate analytical performance and, in case of underperformance, to help them identify sources of errors so that the necessary measures for quality improvement can be taken.

TEST ITEM

Ca. 10 g of PPP test Item will be delivered to each participating lab.

TARGET ANALYTES

The analytes are: Azoxystrobin SL, Epoxiconazole SE, Fludioxonil SL, Metalaxyl-M SL, Pyraclostrobin SE, Thiabendazole SL.

SHIPMENT AND RECEIPT OF THE TEST ITEM

The shipment of the Test Item is planned to start on 15th January 2020. If any laboratory will be on holiday in the week of the shipment, please inform the organizer to rearrange shipment. Participants must check the integrity and condition of the materials upon receipt and to report within 48 h if they accept the materials or not.

IMPORTANT DATES

- The shipment of the Test Items is planned to start on 15th January 2020.
- Submission of results and method information should be done by 30th May 2020.

PARTICIPATION FEE

The participation is free of charge.

RELEVANT DOCUMENTS

Participants are encouraged to employ the method typically run in their lab for these analytes.

SUPPORT AND CONTACT INFORMATION

For any questions about the ITPT2019, please mail to
angela.santilio@iss.it or chiara.pompili@iss.it

Best regards,

The ITPT2020 Organizing Team

APPENDIX B
Calendar and list of participants

CALENDAR for the ITPT2020

| Activity | Dates |
|---|--|
| Opening of the ITPT2020 | 7 th November 2019 |
| Confirm the participation | 30 th November 2019 |
| Shipment of the ITPT2020 Test Item | 15 th January 2020 |
| Confirmation of Sample Receipt and Acceptance | Within 48 h of receipt |
| Result Submission | 30 th January – 30 th April 2020 |
| Preliminary Report | June 2020 |
| Final Report | July 2020 |

LIST OF PARTICIPANTS**Italian participants**

| | |
|----------------------|--|
| Cecilia Capannesi | <i>Laboratorio Sanità Pubblica Firenze</i> |
| Luca D'Ambrosio | <i>Agenzia Provinciale per l'Ambiente – Bolzano</i> |
| Francesca Ferrieri | <i>Polo Alimenti ARPA Puglia</i> |
| Luigi Bazzani | <i>ARPA Emilia Romagna, Sede secondaria laboratorio Multisito, sezione di Ferrara</i> |
| Leonardo Sabatino | <i>Ministero delle Politiche Agricole Alimentari e Forestali, Ispettorato centrale della tutela della qualità e repressione frodi dei prodotti agroalimentari - Laboratorio di Catania</i> |
| Antonella Salzarulo | <i>ARPA Piemonte – Laboratorio Specialistico Nord Ovest</i> |
| Chiara Pompili | <i>Istituto Superiore di Sanità, Roma</i> |
| Pierangela Rovellini | <i>INNOVHUB – SSOG, Milano</i> |
| Andrea Vantini | <i>ARPA Veneto, Verona</i> |

Worldwide participants

| | |
|---------------------|---|
| Lajos Sándor Benke | <i>National Food Chain Safety Office- Hungary</i> |
| Florentina Ciotea | <i>National Phytosanitary Authority - Romania</i> |
| Amelie Coste | <i>Service Commun des Laboratories – Lyon, France</i> |
| Frantisek Csicsay | <i>ÚKSÚP - Bratislava, Slovakia</i> |
| Christoph Czerwenka | <i>AGES GmbH - Wien, Austria</i> |
| Kristina Dürkop | <i>Federal Office of Consumer Protection and Food Safety</i> |
| Jim Garvey | <i>The Pesticide Laboratory Control - Backweston, Ireland</i> |
| Kati Hakala | <i>Finnish Food Safety Authority EVIRA- Helsinki, Finland</i> |
| Eva Jacobsen | <i>Danish Technological Institute - Aarhus, Denmark</i> |
| Helen Karasali | <i>Benaki Phytopathological Institute – Athens, Greece</i> |
| Marek Miszczyk | <i>Institute of Plant Protection, National Research Institute - Sośnicowice, Poland</i> |
| Isabelle Monisse | <i>Laboratory of safety Food Agency – Wandre, Belgium</i> |
| Olga Nováková | <i>UKZUZ National Reference Laboratory – Brno, Czech Republic</i> |
| Vasilav Penev | <i>Bulgaria</i> |
| Estela Bonilha | <i>Ministero da Agricultura, Pecuaria e Abastecimento LFDA/SP – CGAL, Campinas - Brasil</i> |
| Andrew Plumb | <i>Fera Science Ltd – York, UK</i> |
| Ignacio Tristano | <i>Agrofina – Laboratorio de Desarrollo Analitico, Buenos Aires - Argentina</i> |

GLOSSARY

Active Ingredient. An Active Ingredient (AI) is the ingredient in a pharmaceutical drug or plant-health drug that is biologically active. Some products may contain more than one active ingredient.

Analyte. An analyte, component, or chemical species is a substance or chemical constituent that is of interest in an analytical procedure.

CAS number. A CAS Registry Number, also referred to as CASRN or CAS Number, is a unique numerical identifier assigned by the Chemical Abstracts Service (CAS) to every chemical substance described in the open scientific literature (currently including all substances described from 1957 through the present, plus some substances from the early or mid-1900s) including organic and inorganic compounds, minerals, isotopes, alloys and no structural materials (UVCBs, of unknown, variable composition, or biological origin). The registry maintained by CAS is an authoritative collection of disclosed chemical substance information. It currently identifies more than 141 million unique organic and inorganic substances and 67 million protein and DNA sequences, plus additional information about each substance. It is updated with around 15,000 additional new substances daily.

Chemical formula. A chemical formula is a way that chemists describe a molecule. The formula says what atoms, and how many of each type, are in the molecule. Sometimes the formula shows how the atoms are linked, and sometimes the formula shows how the atoms are arranged in space. The letter shows what chemical element each atom is.^[1] The subscript shows the number of each type of atom.

% CV. The coefficient of variation (CV) is defined as the ratio of the standard deviation σ to the mean μ multiplied 100: $CV = (\sigma / \mu) \times 100$.

E isomer. It is the IUPAC convention of a molecular configuration, if the two groups of higher priority are on opposite sides of the double bond, the bond is assigned the configuration E (from the German word for “opposite” *entgegen*).

Grand Average. The grand mean or average is the mean of the means of several subsamples, as long as the subsamples have the same number of data points. For example, consider several lots, each containing several items. The items from each lot are sampled for a measure of some variable and the means of the measurements from each lot are computed. The mean of the measures from each lot constitutes the subsample mean. The mean of these subsample means is then the grand mean.

Homogeneity. Homogeneity and heterogeneity are concepts often used in the sciences and statistics relating to the uniformity in a substance or organism. A material or image that is homogeneous is uniform in composition or character (i.e., colour, shape, size, weight, height, distribution, texture, language, income, disease, temperature, radioactivity, architectural design, etc.); one that is heterogeneous is distinctly non uniform in one of these qualities.

Internal Standard. An internal standard in analytical chemistry is a chemical substance that is added in a constant amount to samples, the blank and calibration standards in a chemical analysis. This substance can then be used for calibration by plotting the ratio of the analyte signal to the internal standard signal as a function of the analyte concentration of the standards. This is done to correct for the loss of analyte during sample preparation or sample inlet. The internal standard is a compound that is very similar, but not identical to the chemical species of interest in the samples, as the effects of sample preparation should, relative to the amount of each species, be the same for the signal from the internal standard as for the signal(s) from the species of interest in the ideal case.

MAD. In statistics, the Median Absolute Deviation (MAD) is a robust measure of the variability of a univariate sample of quantitative data. $MAD = \text{median}(|X_i - \text{median}(X_i)|_{i=1,2,\dots,n})$.

Median. The median is the value separating the higher half of a data sample, a population, or a probability distribution, from the lower half. For a data set, it may be thought of as the “middle” value. For a continuous probability distribution, the median is the value such that a number is equally likely to fall above or below it. The median is a commonly used measure of the properties of a data set in statistics and probability theory. The basic advantage of the median in describing data compared to the mean (often simply described as the “average”) is that it is not skewed so much by extremely large or small values, and so it may give a better idea of a “typical” value. Because of this, the median is of central importance in robust statistics.

Modified z-score. The z-score of an observation is defined as $Z_i = (X_i - \mu) / \sigma$, where X is a sample, μ the sample mean and σ the standard deviation. In other words, data is given in units of how many standard deviations it is from the mean. Although it is common practice to use z-scores to identify possible outliers, this can be misleading in particularly for small sample sizes, so is better to use the modified z-score:

$$Z_i = 0.6745 \times \frac{(X_i - \text{median})}{\text{MAD}}$$

The modified z-scores with an absolute value of greater or lower than 3.5 be labelled as an outlier.

Outlier. An outlier is an observation that appears to deviate markedly from other observations in the sample. Identify potential outliers is important because it may indicate a bad data. For example, the data may have been coded incorrectly or an experiment may not have been run correctly. If it can be determined that an outlying point is in fact erroneous, then the outlying value should be deleted from the analysis (or corrected if possible). If it is not possible to simply delete the outlying observation, the use of robust statistical techniques may be considered.

Reference Method. A reference method is an analytic procedure sufficiently free of random or systemic errors to make it useful for validating proposed new analytic procedures for the same analyte. This method has to be accuracy of a definitive method already certified demonstrated through direct comparison and must use primary reference material (standards, glasses, instruments). An in-house method it means that the method is not certified and made with the laboratory's instruments and techniques. The CIPAC methods is an analytical method make following CIPAC's instructions as the Manufacturer's method is make with the Manufacturer's instructions.

SD. The standard deviation (SD, also represented by the Greek letter sigma σ or the Latin letter s) is a measure that is used to quantify the amount of variation or dispersion of a set of data values. A low standard deviation indicates that the data points tend to be close to the mean of the set, while a high standard deviation indicates that the data points are spread out over a wider range of values.

Stability. The stability is a molecular characteristic of a chemical or compound; is the tendency of a material to resist change or decomposition in its natural environment or when exposed to air, heat, light, pressure or other natural conditions or due to internal reaction.

Z isomer. It is the IUPAC convention of a molecular configuration, if the two groups of higher priority are on the same side of the double bond, the bond is assigned the configuration Z (from the German word for “together” *zusammen*).

*Serie Rapporti ISTISAN
numero di settembre 2020, 2° Suppl.*

*Stampato in proprio
Servizio Comunicazione Scientifica – Istituto Superiore di Sanità*

Roma, settembre 2020